最高56亿美元！创新药BD出海持续火爆，把握港股通创新药ETF（520880）布局窗口

Core Insights - The total value of China's innovative drug BD (business development) outbound licensing transactions reached $135.655 billion in 2025, with a total of 157 deals, both setting historical records [2][19] - The trend of innovative drug BD transactions continues to be strong in 2026, with several significant deals already completed, including a record $5.6 billion deal by Rongchang Biopharma [12][20] Group 1: Innovative Drug Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) is fully invested in innovative drug R&D companies, showcasing high purity, elasticity, and aggressiveness in the rebound market [3][4] - The index of ETF 520880 has outperformed its peers since 2025, with returns of 77.60%, 74.61%, and 72.06% compared to other indices [5][16] - The historical annual returns for the index from 2021 to 2025 were -22.72%, -16.48%, -19.76%, -14.16%, and 66.32% [6][16] Group 2: Key Transactions in 2026 - Notable transactions in 2026 include Rongchang Biopharma's deal with AbbVie for $49.5 billion, and other significant deals involving companies like Zai Lab and Hai Si Ke [12][20] - The highest milestone payments and upfront payments for these transactions indicate a robust market for innovative drugs, with several companies achieving substantial financial commitments [20]